USPTO Grants BetterLife’s BETR-001 Composition of Matter Patent
BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), an emerging biotech company, announced that the USPTO has granted the BETR-001 composition of matter patent (US2023/0219955), expiring in 2042. BETR-001 is a non-hallucinogenic derivative of LSD. This new patent adds to BetterLife's existing intellectual property, which includes patents for the synthesis of 2-bromo-LSD (US9,868,732B2 and US10,377,752B2) issued in 2018 and 2019.
Dr. Ahmad Doroudian, CEO of BetterLife, stated that this patent is a significant milestone, ensuring the commercial potential of BETR-001, the R:R stereoisomer of 2-bromo-LSD. BetterLife is the first to demonstrate that the R:R stereoisomer is active at the neuroreceptors involved in treating various mental health disorders.
The company is actively pursuing additional claims such as method-of-use and has filed other patent applications covering BETR-001 and other forms of 2-bromo-LSD. BetterLife is confident in its strong intellectual property position and the commercial viability of BETR-001.
BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), un'azienda biofarmaceutica emergente, ha annunciato che l'USPTO ha concesso il brevetto per la composizione del BETR-001 (US2023/0219955), con scadenza nel 2042. BETR-001 è un derivato non allucinogeno dell'LSD. Questo nuovo brevetto si aggiunge alla proprietà intellettuale esistente di BetterLife, che include brevetti per la sintesi del 2-bromo-LSD (US9,868,732B2 e US10,377,752B2) rilasciati nel 2018 e nel 2019.
Il Dr. Ahmad Doroudian, CEO di BetterLife, ha dichiarato che questo brevetto rappresenta un traguardo significativo, garantendo il potenziale commerciale di BETR-001, lo stereoisomero R:R del 2-bromo-LSD. BetterLife è la prima a dimostrare che lo stereoisomero R:R è attivo nei neurorecettori coinvolti nel trattamento di vari disturbi della salute mentale.
L'azienda sta perseguendo attivamente ulteriori rivendicazioni, come il metodo d'uso e ha presentato altre domande di brevetto che coprono BETR-001 e altre forme di 2-bromo-LSD. BetterLife è fiduciosa nella sua forte posizione di proprietà intellettuale e nella viabilità commerciale di BETR-001.
BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), una empresa biofarmacéutica emergente, anunció que el USPTO ha concedido la patente de composición del BETR-001 (US2023/0219955), que expira en 2042. BETR-001 es un derivado no alucinógeno del LSD. Esta nueva patente se suma a la propiedad intelectual existente de BetterLife, que incluye patentes para la síntesis de 2-bromo-LSD (US9,868,732B2 y US10,377,752B2) emitidas en 2018 y 2019.
El Dr. Ahmad Doroudian, CEO de BetterLife, declaró que esta patente es un hito importante, asegurando el potencial comercial de BETR-001, el estereoisómero R:R del 2-bromo-LSD. BetterLife es la primera en demostrar que el estereoisómero R:R es activo en los neuroreceptores involucrados en el tratamiento de varios trastornos de salud mental.
La empresa está persiguiendo activamente reclamaciones adicionales, como el método de uso y ha presentado otras solicitudes de patente que cubren el BETR-001 y otras formas de 2-bromo-LSD. BetterLife confía en su sólida posición de propiedad intelectual y en la viabilidad comercial de BETR-001.
BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), 새로운 생명 과학 기업이 미국 특허청(USPTO)으로부터 BETR-001 물질 조성 특허 (US2023/0219955)를 받았으며, 해당 특허는 2042년에 만료됩니다. BETR-001은 환각작용이 없는 LSD 유도체입니다. 이번 특허는 BetterLife의 기존 지적 재산에 추가된 것으로, 2018년과 2019년에 발행된 2-bromo-LSD의 합성에 대한 특허를 포함하고 있습니다 (US9,868,732B2 및 US10,377,752B2).
BetterLife의 CEO인 Dr. Ahmad Doroudian은 이 특허가 중요한 이정표이며, 2-bromo-LSD의 R:R 스테레오이소머인 BETR-001의 상업적 가능성을 보장한다고 밝혔습니다. BetterLife는 R:R 스테레오이소머가 다양한 정신 건강 장애 치료에 관여하는 신경 수용체에서 활성화된다는 점을 최초로 입증한 기업입니다.
회사는 사용 방법과 같은 추가 청구를 적극적으로 추진하고 있으며 BETR-001 및 기타 형태의 2-bromo-LSD에 대한 다른 특허 출원도 제출했습니다. BetterLife는 자기 강력한 지적 재산의 위치와 BETR-001의 상업적 실행 가능성에 대해 자신감을 갖고 있습니다.
BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), une entreprise biopharmaceutique émergente, a annoncé que l'USPTO a accordé le brevet pour la composition BETR-001 (US2023/0219955), qui expirera en 2042. BETR-001 est un dérivé non hallucinogène du LSD. Ce nouveau brevet vient s'ajouter à la propriété intellectuelle existante de BetterLife, qui inclut des brevets pour la synthèse de 2-bromo-LSD (US9,868,732B2 et US10,377,752B2) délivrés en 2018 et 2019.
Le Dr Ahmad Doroudian, PDG de BetterLife, a déclaré que ce brevet constitue une étape importante, garantissant le potentiel commercial de BETR-001, le stéréoisomère R:R du 2-bromo-LSD. BetterLife est la première à démontrer que le stéréoisomère R:R est actif sur les neurorécepteurs impliqués dans le traitement de divers troubles de la santé mentale.
L'entreprise poursuit activement des revendications supplémentaires telles que le mode d'utilisation et a déposé d'autres demandes de brevet couvrant BETR-001 et d'autres formes de 2-bromo-LSD. BetterLife est confiante dans sa solide position en matière de propriété intellectuelle et la viabilité commerciale de BETR-001.
BetterLife Pharma (CSE: BETR, OTCQB: BETRF, FRA: NPAU), ein aufstrebendes Biotechnologieunternehmen, gab bekannt, dass das USPTO das BETR-001 Zusammensetzungs-Patent (US2023/0219955) bis 2042 erteilt hat. BETR-001 ist ein nicht-halluzinogener Derivat von LSD. Dieses neue Patent ergänzt das bestehende geistige Eigentum von BetterLife, das Patente für die Synthese von 2-bromo-LSD (US9,868,732B2 und US10,377,752B2), welche 2018 und 2019 erteilt wurden, umfasst.
Dr. Ahmad Doroudian, CEO von BetterLife, erklärte, dass dieses Patent einen bedeutenden Meilenstein darstellt, der das kommerzielle Potenzial von BETR-001, dem R:R Stereoisomer von 2-bromo-LSD, sichert. BetterLife ist das erste Unternehmen, das nachweist, dass das R:R Stereoisomer an den Neurorezeptoren aktiv ist, die an der Behandlung verschiedener psychischer Erkrankungen beteiligt sind.
Das Unternehmen verfolgt aktiv zusätzliche Ansprüche, wie die Methode der Verwendung und hat weitere Patentanmeldungen eingereicht, die BETR-001 und andere Formen von 2-bromo-LSD abdecken. BetterLife ist zuversichtlich in seiner starken geistigen Eigentumsposition und der kommerziellen Lebensfähigkeit von BETR-001.
- USPTO granted the BETR-001 composition of matter patent, expiring in 2042.
- BETR-001 patent adds to BetterLife's existing intellectual property portfolio.
- The patent ensures the commercial potential of BETR-001.
- BETR-001 is the first to show activity at neuroreceptors involved in treating mental health disorders.
- None.
VANCOUVER, British Columbia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announced that the USPTO has granted the BETR-001 composition of matter patent US publication number US2023/0219955 with expiry in 2042. BetterLife now has multiple layers of intellectual property protection for BETR-001 including previously issued patents for synthesis of 2-bromo-LSD; US9,868,732B2 and US10,377,752B2 which were issued in 2018 and 2019, respectively.
Dr. Ahmad Doroudian, CEO of BetterLife commented, “We are extremely pleased with the grant of these composition of matter claims that cover BETR-001 as well as other forms of 2-bromo-LSD. This is a significant milestone as the issuance of this patent by USPTO ensures the commercial potential of BETR-001 which is the R:R stereoisomer of 2-bromo-LSD. BetterLife is the first to show that, of the four possible 2-bromo-LSD stereoisomers (R:R, R:S, S:R and S:S), the R:R stereoisomer is the one that is active at the neuroreceptors that are involved in the treatment of various mental health disorders.”
He further added, “We are actively pursuing additional claims such as method-of-use and so forth, which were part of the original provisional application. Furthermore, we have separately filed other patent applications that cover BETR-001 as well as other forms of 2-bromo-LSD. Taken together, we are confident about our strong intellectual property position in this field and a strong and highly valuable commercial viability of BETR-001.”
About BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.
BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.
BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.
For further information, please visit BetterLife Pharma.
Contact
David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928
Cautionary Note Regarding Forward-Looking Statements
No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is the USPTO patent granted to BetterLife for BETR-001?
What does the BETR-001 patent mean for BetterLife shareholders?
How does the BETR-001 patent impact BetterLife's intellectual property?
When does the BETR-001 patent expire?
What is the significance of the R:R stereoisomer in BETR-001?
What additional claims is BetterLife pursuing for BETR-001?
